Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814307 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis
A Phase 3 study of Arthritis, Rheumatoid, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 611
- Enrollment target
- 20
- Study locations
NCT00814307 is a Phase 3 study of Arthritis, Rheumatoid that has completed, run by Pfizer. The registered enrollment target is 611 participants, roughly in line with the 619-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target. The trial reports 20 study locations across 11 states.
The verdict
NCT00814307, a Phase 3 study of Arthritis, Rheumatoid, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 611 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 Rheumatoid Arthritis studies.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CP-690,550
Study Locations (20)
Florida
- Pfizer Investigational Site - Jacksonville
- Pfizer Investigational Site - Sarasota
- Pfizer Investigational Site - Tampa
- Pfizer Investigational Site - Venice
- Pfizer Investigational Site - Zephyrhills
New York
- Pfizer Investigational Site - Albany
- Pfizer Investigational Site - Olean
- Pfizer Investigational Site - Rochester
North Carolina
- Pfizer Investigational Site - Charlotte
- Pfizer Investigational Site - Rocky Mount
- Pfizer Investigational Site - Winston-Salem
Arizona
- Pfizer Investigational Site - Gilbert
- Pfizer Investigational Site - Tucson
Arkansas
- Pfizer Investigational Site - Hot Springs
Illinois
- Pfizer Investigational Site - Rockford
Maryland
- Pfizer Investigational Site - Frederick
Massachusetts
- Pfizer Investigational Site - Hyannis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 611 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00814307
The ClinicalTrials.gov registry entry for NCT00814307 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 611 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 619-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00814307 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00814307 about?
NCT00814307 is a clinical study titled "A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis". This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and ph...
What is the current status of trial NCT00814307?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 611 participants. The study started on 2009-02. Estimated completion is 2010-06.
What conditions does trial NCT00814307 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT00814307?
The interventions under investigation include: Placebo (DRUG), CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT00814307?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00814307 being conducted?
This trial has 20 study locations across Arizona, Arkansas, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
COMPLETED · Phase 3
-
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
COMPLETED · Phase 3
-
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.